Ulla Hedner

Summary

Affiliation: Novo Nordisk A/S
Country: Denmark

Publications

  1. ncbi request reprint FVIIa as therapeutic agent in hemophilia and beyond
    Ulla Hedner
    Department of Medicine, Malmo University Hospital, University of Lund, Malmo, Sweden
    Front Biosci (Elite Ed) 4:1210-23. 2012
  2. ncbi request reprint Recombinant factor VIIa (rFVIIa): its potential role as a hemostatic agent
    Ulla Hedner
    University of Lund, Lund, Sweden
    Neuroradiology 49:789-93. 2007
  3. ncbi request reprint General haemostatic agents--fact or fiction?
    Ulla Hedner
    Novo Nordisk A S, Copenhagen, Denmark
    Pathophysiol Haemost Thromb 32:33-6. 2002
  4. ncbi request reprint Mechanism of action of factor VIIa in the treatment of coagulopathies
    Ulla Hedner
    University of Lund, Malmo, Sweden
    Semin Thromb Hemost 32:77-85. 2006
  5. ncbi request reprint Mechanism of action of recombinant activated factor VII: an update
    Ulla Hedner
    University of Lund, Sweden
    Semin Hematol 43:S105-7. 2006
  6. ncbi request reprint Potential role for rFVIIa in transfusion medicine
    Ulla Hedner
    Novo Nordisk A S Research and Development, Bagsvaerd, Denmark
    Transfusion 42:114-24. 2002
  7. ncbi request reprint Tissue factor and factor VIIa as therapeutic targets in disorders of hemostasis
    Ulla Hedner
    Department of Medicine, University of Lund, Sweden
    Annu Rev Med 59:29-41. 2008
  8. ncbi request reprint Recombinant FVIIa
    U Hedner
    Professor of Clinical Coagulation Research, Lund University, Sweden
    Vox Sang 87:25-8. 2004
  9. ncbi request reprint Potential role of recombinant factor VIIa as a hemostatic agent
    Ulla Hedner
    University of Lund, Sweden
    Clin Adv Hematol Oncol 1:112-9. 2003
  10. doi request reprint Prevention of arthropathy: may it be extrapolated from patients without inhibitors to patients with inhibitors?
    U Hedner
    University of Lund, Sweden and Research and Development, Novo Nordisk A S, Bagsvaerd, Denmark
    Haemophilia 14:23-7. 2008

Collaborators

Detail Information

Publications44

  1. ncbi request reprint FVIIa as therapeutic agent in hemophilia and beyond
    Ulla Hedner
    Department of Medicine, Malmo University Hospital, University of Lund, Malmo, Sweden
    Front Biosci (Elite Ed) 4:1210-23. 2012
    ..In case of impaired thrombin generation, loose fibrin plugs easily dissolved are formed. Extra rFVIIa enhances thrombin generation and generates tight fibrin plugs...
  2. ncbi request reprint Recombinant factor VIIa (rFVIIa): its potential role as a hemostatic agent
    Ulla Hedner
    University of Lund, Lund, Sweden
    Neuroradiology 49:789-93. 2007
    ..The importance of platelets and platelet membrane phospholipids in hemostasis has been demonstrated, and the new concept of the hemostatic process, focusing on cell surfaces, has been outlined...
  3. ncbi request reprint General haemostatic agents--fact or fiction?
    Ulla Hedner
    Novo Nordisk A S, Copenhagen, Denmark
    Pathophysiol Haemost Thromb 32:33-6. 2002
    ..Let us look forward to more 'facts' through the 'evidence-based route'...
  4. ncbi request reprint Mechanism of action of factor VIIa in the treatment of coagulopathies
    Ulla Hedner
    University of Lund, Malmo, Sweden
    Semin Thromb Hemost 32:77-85. 2006
    ..Local fibrinolytic activity also occurs in the gastrointestinal tract as well as during profuse postpartum bleeding. Pharmacologic doses of rFVIIa induce hemostasis in these cases also...
  5. ncbi request reprint Mechanism of action of recombinant activated factor VII: an update
    Ulla Hedner
    University of Lund, Sweden
    Semin Hematol 43:S105-7. 2006
    ..This mechanism explains the reported efficacy of rFVIIa in a range of clinical situations characterized by impaired thrombin generation...
  6. ncbi request reprint Potential role for rFVIIa in transfusion medicine
    Ulla Hedner
    Novo Nordisk A S Research and Development, Bagsvaerd, Denmark
    Transfusion 42:114-24. 2002
  7. ncbi request reprint Tissue factor and factor VIIa as therapeutic targets in disorders of hemostasis
    Ulla Hedner
    Department of Medicine, University of Lund, Sweden
    Annu Rev Med 59:29-41. 2008
    ..Inhibition of the FVII-TF-dependent pathway (TFPI and rFVIIai) has been tried in attempts to prevent thrombosis, with promising results in animal models so far not confirmed in clinical trials...
  8. ncbi request reprint Recombinant FVIIa
    U Hedner
    Professor of Clinical Coagulation Research, Lund University, Sweden
    Vox Sang 87:25-8. 2004
  9. ncbi request reprint Potential role of recombinant factor VIIa as a hemostatic agent
    Ulla Hedner
    University of Lund, Sweden
    Clin Adv Hematol Oncol 1:112-9. 2003
    ..rFVIIa has also been successfully used in acute trauma patients with profuse bleedings and in other bleeding situations...
  10. doi request reprint Prevention of arthropathy: may it be extrapolated from patients without inhibitors to patients with inhibitors?
    U Hedner
    University of Lund, Sweden and Research and Development, Novo Nordisk A S, Bagsvaerd, Denmark
    Haemophilia 14:23-7. 2008
    ....
  11. ncbi request reprint Factor VIIa and its potential therapeutic use in bleeding-associated pathologies
    Ulla Hedner
    Novo Nordisk A S, Novo Alle, Bagsvaerd, Denmark
    Thromb Haemost 100:557-62. 2008
    ..A special form of profuse bleeding, that may cause extensive problems is postpartum haemorrhage...
  12. doi request reprint History of rFVIIa therapy
    Ulla Hedner
    Department of Medicine, Malmo University Hospital, University of Lund, Malmo, Sweden
    Thromb Res 125:S4-6. 2010
    ..The initial thrombin generation is generated by the formation of the TF-FVIIa-complex formed initially on the TF-bearing cells...
  13. doi request reprint First 20 years with recombinant FVIIa (NovoSeven)
    U Hedner
    Department of Medicine, University of Lund, Lund, Sweden
    Haemophilia 17:e172-82. 2011
    ..By exploiting this mechanism of action, rFVIIa may also be effective in situations other than haemophilia, characterized by an impaired thrombin generation...
  14. ncbi request reprint The effect of platelets on fibrin gel structure formed in the presence of recombinant factor VIIa in hemophilia plasma and in plasma from a patient with Glanzmann thrombasthenia
    S He
    Department of Surgical Sciences, Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden
    J Thromb Haemost 3:272-9. 2005
    ..Annexin V blocked any effect of rFVIIa. A normalization of the overall fibrinolysis potential (OFP) during the same condition supports the effect of rFVIIa on the fibrin permeability in the presence of a limited number of platelets...
  15. ncbi request reprint Recombinant factor VIIa: its background, development and clinical use
    Ulla Hedner
    University of Lund, Sweden
    Curr Opin Hematol 14:225-9. 2007
    ..For the first time it was shown that pharmacological doses of FVIIa induced hemostasis...
  16. ncbi request reprint Mechanism of action, development and clinical experience of recombinant FVIIa
    Ulla Hedner
    University of Lund, Sweden
    J Biotechnol 124:747-57. 2006
    ..Pharmacological doses of rFVIIa have in fact, also been shown to induce hemostasis in such cases...
  17. ncbi request reprint rFVIIai in Acute Coronary Syndromes
    Brit Binow Sorensen
    Haemostasis Biology, Novo Nordisk A S, Maaløv, Denmark
    Semin Vasc Med 3:199-204. 2003
    ..In a limited number of patients undergoing percutaneous transluminal coronary angioplasty (PTCA), rFVIIai was observed to allow PTCA to be performed at lower doses of heparin than what has been reported previously...
  18. ncbi request reprint A study of the pharmacokinetics and safety of recombinant activated factor VII in healthy Caucasian and Japanese subjects
    Marianne J Fridberg
    Novo Nordisk A S, Krogshoejvej 55, DK 2880 Bagsvaerd, Denmark
    Blood Coagul Fibrinolysis 16:259-66. 2005
    ..In conclusion, the pharmacokinetics of rFVIIa in Caucasian and Japanese subjects are similar, and no safety issues were identified...
  19. ncbi request reprint The role of recombinant factor VIIa (FVIIa) in fibrin structure in the absence of FVIII/FIX
    S He
    Coagulation Research, Department of Surgical Sciences, Unit of Clinical Allergy Research, Karolinska Institutet, Karolinska Hospital, Stockholm, Sweden
    J Thromb Haemost 1:1215-9. 2003
    ..The addition of rFVIIa to FVIII- or FIX-deficient systems altered the network structure, making the fibers thinner and more tightly packed...
  20. ncbi request reprint Evaluation of potential antigenicity of active-site-inhibited recombinant human FVIIa (FFR-rFVIIa) in an immune-tolerant rat model
    Else Marie Nicolaisen
    NovoSeven Research, Novo Nordisk A S, Måløv, Denmark
    Thromb Haemost 87:836-9. 2002
    ..Repeated intravenous administration of different dosages of FFR-rFVIIa did not break tolerance, indicating that FFR-rFVIIa might not be antigenic, for a limited number of intravenous administrations in a clinical setting...
  21. ncbi request reprint High-dose factor VIIa increases initial thrombin generation and mediates faster platelet activation in thrombocytopenia-like conditions in a cell-based model system
    M Kjalke
    Vascular Biochemistry, Novo Nordisk, Måløv, Denmark
    Br J Haematol 114:114-20. 2001
    ....
  22. doi request reprint Recombinant human factor VIIa and a factor VIIa-analogue reduces heparin and low molecular weight heparin (LMWH)-induced bleeding in rats
    B Lauritzen
    Research and Development, Novo Nordisk A S, Måløv, Denmark
    J Thromb Haemost 6:804-11. 2008
    ..Heparin can readily be antagonized with protamine, but this is less effective against LMWH...
  23. pmc Recombinant human factor VIIa (rFVIIa) cleared principally by antithrombin following intravenous administration in hemophilia patients
    H Agersø
    Pharmacology, Biopharmaceuticals Research Unit, Novo Nordisk A S, Maaloev, Denmark
    J Thromb Haemost 9:333-8. 2011
    ..The objective of the present study was to evaluate the pharmacokinetics and the clearance pathways of rFVIIa after intravenous administration to hemophilia patients...
  24. ncbi request reprint Effect of active site-inactivated factor VIIa on ischaemia/reperfusion injury in a porcine flap model
    Torbjörn Söderström
    Department of Plastic and Reconstructive Surgery, University Hospital, Malmo, Sweden
    Scand J Plast Reconstr Surg Hand Surg 38:326-34. 2004
    ..We conclude that FFR-rFVIIa did not prevent IR injury, indicating that tissue factor-mediated coagulation is not an important determinant of IR injury in this setting...
  25. ncbi request reprint Active site-inactivated factor VIIa prevents thrombosis without increased surgical bleeding: topical and intravenous administration in a rat model of deep arterial injury
    T Soderstrom
    Department of Plastic and Reconstructive Surgery, University Hospital, Malmo, Sweden
    J Vasc Surg 33:1072-9. 2001
    ..This hypothesis was tested with a rat model of arterial thrombosis...
  26. ncbi request reprint Recombinant factor VIIa (Novoseven) as a hemostatic agent
    U Hedner
    Novo Nordisk A S, Research and Development, Maaloev, Denmark
    Semin Hematol 38:43-7. 2001
    ..Recent in vitro experiments indicate that even higher doses of NovoSeven may be needed to achieve full thrombin generation in the absence of factor VIII (FVIII), factor IX (FIX), and factor XI (FXI)...
  27. ncbi request reprint Effect of locally-applied active site-blocked activated factor VII (ASIS) on experimental arterial thrombosis
    B Arnljots
    Department of Plastic and Reconstructive Surgery, The University Hospital, Malmo, Sweden
    Blood Coagul Fibrinolysis 11:S145-8. 2000
    ..This mode of treatment may have a potential for a variety of clinical interventions in injured or diseased vessels...
  28. ncbi request reprint The effect of recombinant factor VIIa (NovoSeven) in healthy volunteers receiving acenocoumarol to an International Normalized Ratio above 2.0
    E Erhardtsen
    Novo Nordisk A S, Copenhagen, Denmark
    Blood Coagul Fibrinolysis 9:741-8. 1998
    ..Fragment 1+2 stayed within its normal range in all dose groups, indicating that no systemic coagulation occurred...
  29. ncbi request reprint NovoSeven as a universal haemostatic agent
    U Hedner
    Novo Nordisk A S, Health Care Discovery, Gentofte, Denmark
    Blood Coagul Fibrinolysis 11:S107-11. 2000
    ..Recombinant FVIIa has also been shown to normalize prothrombin time in patients with liver disease and in warfarin-treated individuals...
  30. ncbi request reprint NovoSeven in warfarin-treated patients
    E Berntorp
    Department for Coagulation Disorders, Lund University, University Hospital, Malmo, Sweden
    Blood Coagul Fibrinolysis 11:S113-5. 2000
    ..When rFVIIa was given to a patient with a warfarin-induced nosebleed, it had an immediate haemostatic effect and the International Normalized Ratio value virtually normalized...
  31. ncbi request reprint Recombinant activated factor VII as a universal haemostatic agent
    U Hedner
    Novo Nordisk A S, Health Care Discovery, Gentofte, Denmark
    Blood Coagul Fibrinolysis 9:S147-52. 1998
    ....
  32. ncbi request reprint Amino acid sequence and posttranslational modifications of human factor VIIa from plasma and transfected baby hamster kidney cells
    L Thim
    Novo Research Institute, Bagsvaerd, Denmark
    Biochemistry 27:7785-93. 1988
    ..Besides minor differences in the sialic acid and fucose contents, the overall carbohydrate compositions were nearly identical in recombinant factor VIIa and human plasma factor VIIa.(ABSTRACT TRUNCATED AT 250 WORDS)..
  33. ncbi request reprint Initial inhibition of tissue factor signalling reduces chronic vascular changes in isogenic rat aortic transplants
    C Osterholm
    Department of Nephrology and Transplantation, Lund University, University Hospital, , Sweden
    Am J Transplant 1:29-37. 2001
    ..We conclude that active site inhibited FVIIa (rFVIIai) given prior to and directly after implantation of aortic transplants significantly reduces intimal hyperplasia caused by nonimmunological factors in this model...
  34. ncbi request reprint Future possibilities in the regulation of the extrinsic pathway: rFVIIa and TFPI
    U Hedner
    Wallenberg Laboratory, University Hospital Malmo, University of Lund, Sweden
    Ann Med 32:68-72. 2000
    ..Recombinant TFPI has been shown to attenuate the lethal inflammatory and coagulopathic response. Furthermore, topical application of rFVIIai has been found to increase the patency rate in a model of graft surgery...
  35. ncbi request reprint Anti- and procoagulant activities in factor VII-deficient subjects
    J Astermark
    Department of Coagulation Disorders, University Hospital, University of Lund, Malmo, Sweden
    Thromb Res 101:435-40. 2001
    ..Whether this could influence the clinical feature, including the risk of thromboembolic events in association with replacement therapy, remains to be evaluated...
  36. ncbi request reprint High dose factor VIIa improves clot structure and stability in a model of haemophilia B
    Alisa S Wolberg
    Department of Pathology and Laboratory Medicine, University of North Carolina at Chapel Hill, NC 27599 7525, USA
    Br J Haematol 131:645-55. 2005
    ....
  37. ncbi request reprint Dosing with recombinant factor viia based on current evidence
    Ulla Hedner
    Research and Development, Novo Nordisk, Denmark
    Semin Hematol 41:35-9. 2004
    ..Optimal doses may thus vary not only between hemophilia patients, but also between patients treated for other bleeding disorders...
  38. ncbi request reprint The effect of recombinant factor VIIa on noncoagulopathic pigs with grade V liver injuries
    Martin A Schreiber
    Department of Surgery and Medicine, Baylor College of Medicine, Houston, TX, USA
    J Am Coll Surg 196:691-7. 2003
    ..This study was performed to determine if rFVIIa would reduce blood loss after a Grade V liver injury in noncoagulopathic pigs when used as sole therapy...
  39. ncbi request reprint Recombinant factor VIIa increases the pressure at which rebleeding occurs in porcine uncontrolled aortic hemorrhage model
    Jill L Sondeen
    U S Army Institute of Surgical Research, Fort Sam Houston, Texas 78234, USA
    Shock 22:163-8. 2004
    ....
  40. doi request reprint Recombinant factor VIIa reduces rebleed hemorrhage volume in a swine aortotomy model: a randomized double-blinded study
    Neil R McMullin
    US Army Institute of Surgical Research, San Antonio, Texas, USA
    Shock 29:703-8. 2008
    ....
  41. ncbi request reprint Recombinant factor VIIa (NovoSeven) as a hemostatic agent
    Ulla Hedner
    Dis Mon 49:39-48. 2003
    ..Recent in vitro experiments indicate that even higher doses of NovoSeven may be needed to achieve full thrombin generation in the absence of factor VIII (FVIII), factor IX (FIX), and factor XI (FXI)...
  42. ncbi request reprint The effect of recombinant factor VIIa on coagulopathic pigs with grade V liver injuries
    Martin A Schreiber
    Michael E DeBakey Department of Surgery, Baylor College of Medicine, University of Texas at Houston, Houston, Texas, USA
    J Trauma 53:252-7; discussion 257-9. 2002
    ....
  43. ncbi request reprint A variant of recombinant factor VIIa with enhanced procoagulant and antifibrinolytic activities in an in vitro model of hemophilia
    Geoffrey A Allen
    Department of Pediatrics, University of North Carolina, Chapel Hill, NC, USA
    Arterioscler Thromb Vasc Biol 27:683-9. 2007
    ..The aim of this work was to define the effects of NN1731 toward factor X activation, platelet activation, thrombin generation, and fibrin clot formation and stability...
  44. ncbi request reprint Cutaneous wound healing is impaired in hemophilia B
    Maureane Hoffman
    Laboratory Service 113, Durham Veterans Affairs Medical Center, 508 Fulton St, Durham, NC 27705, USA
    Blood 108:3053-60. 2006
    ..Our findings have significant implications for treatment of patients with hemophilia, and also highlight the importance of rapidly establishing hemostasis following trauma or surgery...